Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 5200 participants.
Also called NCT05105321
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 5,200 participants
- Registry
-
NCT05105321
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT05105321. Randomized; triple masking; primary purpose prevention. Start 2021-12 (anticipated); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
- Acronym
- CDPP
- Condition
- Metabolic Syndrome
- Intervention (Drug)
- Berberine
- Intervention (Behavioral)
- Healthy lifestyle intervention
- Lead sponsor
- Tang Yida
- Collaborator
- Chinese Society of Cardiology
Record details
- Record id
cardio:ct-nct05105321- Content hash
b03b419117e4f4d3eafe3f6b55f36c60b295cf0c372e0400892bc10b8c4379ee